Nurix Therapeutics, Inc.

NRIXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1549595

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$77.0M	$38.6M	—	—	—
Research and Development Expense	$189.1M	$184.5M	$184.5M	$116.4M	$45.0M
Operating Expenses	$232.1M	$222.5M	$222.5M	$147.6M	$53.4M
Operating Income (Loss)	-$155.1M	-$183.9M	-$183.9M	-$117.9M	-$22.2M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$143.9M	-$180.4M	-$180.4M	-$117.1M	-$21.5M
Income Tax Expense (Benefit)	$0.00	$0.00	—	$131.0K	$239.0K
Net Income (Loss) Attributable to Parent	-$143.9M	-$180.4M	-$180.4M	-$117.2M	-$21.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$669.3M	$355.6M	$416.8M	$476.8M	$396.3M
Assets, Current	$619.4M	$295.5M	$318.4M	$311.1M	$298.4M
Cash and Cash Equivalents, at Carrying Value	$54.6M	$64.5M	$64.5M	$80.5M	$119.4M
Liabilities	$142.3M	$155.1M	$113.1M	$134.5M	$106.1M
Liabilities, Current	$95.9M	$87.0M	$70.7M	$66.3M	$44.5M
Accounts Payable, Current	$11.5M	$6.4M	$5.1M	$6.7M	$3.4M
Stockholders' Equity Attributable to Parent	$303.7M	$342.3M	$342.3M	$290.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$81.4M	-$159.8M	-$159.8M	-$84.4M	$601.0K
Net Cash Provided by (Used in) Investing Activities	$68.3M	$27.2M	$27.2M	-$108.3M	$8.5M
Net Cash Provided by (Used in) Financing Activities	$3.2M	$117.2M	$117.2M	$153.9M	$126.0K
Payments to Acquire Property, Plant, and Equipment	$8.4M	$12.2M	$12.2M	$5.7M	$1.7M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)